Author

Hyejin Ahn

Observed name: Ahn, Hyejin

Institutions: Asan Medical Center, University of Ulsan

Observed institutions: Asan Medical Center, University of Ulsan

ORCID: 0009-0003-9886-7322

Observed ORCID: 0009-0003-9886-7322

OpenAlex ID: A5078780441

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

2022 · Eunsil Sung, Minkyung Ko, et al. · Molecular Therapy · 84

Genome wide CRISPR screening reveals a role for sialylation in the tumorigenesis and chemoresistance of acute myeloid leukemia cells

2021 · Dong-hee Lee, Seong-Ho Kang, et al. · Cancer Letters · 25

A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity

2023 · Dong-hee Lee, Hyejin Ahn, et al. · Journal of Experimental & Clinical Cancer Research · 23

Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2

2025 · Hye-In Sim, Yunju Jo, et al. · BMB Reports · 1

PD-L1-Directed CD226 Agonism Enhances Antitumor Activity by Amplifying T Cell Responses to Limiting Stimulation

2026 · Yunju Jo, Hyejin Ahn, et al. · Immune Network

Erratum to: Modulating CD226 and PD-(L)1 pathways improves CMV-specific CD8＋T cell responses in the absence of IL-2.

2025 · Hye-In Sim, Yunju Jo, et al. · PubMed Central

Works count: 8

Citation count: 133

H-index: 3

I10-index: 3